Muriel Liberto, Ph.D.
Muriel brings a deep technical background and decades of law firm experience to the creation, management, and strategic development of her clients’ patent assets. She provides thoughtful, practical advice on patentability, competitive landscape, and freedom to operate, while helping to ensure that IP strategies remain aligned with changing business goals and priorities.
Whether working with emerging companies, established corporations, universities, or non-profit research institutions, Muriel engages with clients to share knowledge and expertise aimed at developing and protecting innovation in a global economy.
Role/Title
- Partner
Education
- Fordham University, New York, NY, JD, magna cum laude (2006)
- Ohio State University, Columbus, OH, PhD, Biochemistry (1996)
- College of William & Mary, Williamsburg, VA, BS, Chemistry (1991)
Admissions
- Bar: New Jersey; New York
- Other: United States Patent and Trademark Office
Practice Areas
- Patent Counseling
- Patent Drafting and Prosecution
- Due Diligence
- Opinions
- Licensing and Technology
- Transactions
Industries
- Biotechnology
- Bioprocessing
- Pharmaceutical
Notable Legal Expertise
- Patent preparation and world-wide prosecution
- IP due diligence in connection with financings and transactions
- Client counseling in patent portfolio development, management, and strategy in diverse technologies
Representative Technologies Expertise
- Bioprocessing
- Small molecule therapeutics
- Antibodies, vaccines, gene therapy, cell therapy, and molecular diagnostics
- Personalized medicine
- Drug delivery systems
- Affinity chromatography
Experience
- Member, Mintz Levin, New York NY, 2016–2022
- Of Counsel, Mintz Levin, New York NY, 2014–2016
- Associate, Mintz Levin, New York NY, 2008–2014
- Associate, Jones Day, New York NY, 2006–2008
- Patent Agent, Jones Day, New York NY, 2004–2006
- Patent Agent, Cooper & Dunham LLP, New York NY, 2001–2004
Published Content
- Don’t Be Caught without Possession (of Your Invention): What You Need To Know about the Written Description Requirement | By Muriel Liberto and Peter J. Cuomo | | IP Litigator March/April 2021 27(2)
- Personalized Medicine Gets a Boost from the Federal Circuit’s Vanda Pharma Decision | By Muriel M. Liberto, Ph.D. and Jennifer L. Dereka | IP Litigator July/August 2018 24(4)
Speaking Engagements
- JAN 15 2020 | Planning for Success: Integrating Product Development with Intellectual Property and Regulatory Strategies | ELabs NYC New York, NY
- SEP 25 2019 | IP Diligence: Identifying, evaluating, and mitigating risk related to intellectual property; Focus on the Healthcare Sector and Tips for Angel Investors | Golden Seeds NY Investor Forum New York, NY
- JAN 16 2019 | Planning for Success: Integrating Product Development with Intellectual Property and Regulatory Strategies | ELabs NYC New York, NY
- JUN 18 2018 | IP 101 for Emerging Companies | Princeton Innovation Center BioLabs Plainsboro, NJ
- APR 4 2018 | New York Life Science Founders Seminar #10 | BioLabs NYU Langone New York, NY
- JUL 19 2017 | Patent Protection for Pharma and Biotechnology in 2017 | The Knowledge Group Webinar
- MAR 5 2014 | Patentable Subject Matter Pitfalls Affecting the Healthcare Industry | BioIndustry Association (BIA)
Suite 103
Cary, NC 27513
